Skip to Content
Merck
  • Synthesis and evaluation of novel 2-pyridone derivatives as inhibitors of phosphodiesterase3 (PDE3): a target for heart failure and platelet aggregation.

Synthesis and evaluation of novel 2-pyridone derivatives as inhibitors of phosphodiesterase3 (PDE3): a target for heart failure and platelet aggregation.

Bioorganic & medicinal chemistry letters (2012-08-18)
Mettu Ravinder, Budde Mahendar, Saidulu Mattapally, Kommi Venkata Hamsini, Thatikonda Narendar Reddy, Chilappa Rohit, Kolupula Srinivas, Sanjay Kumar Banerjee, Vaidya Jayathirtha Rao
ABSTRACT

Twenty-six 2-pyridone derivatives (8a-8z), which are structurally analogous to amrinone and milrinone two important cardiotonic drugs, are synthesized and characterized. The synthesis of 2-pyridone derivatives involves addition, followed by cyclization between Baylis-Hillman acetates (7a-7k) and enamino esters or nitriles (3a-3e). Thus synthesized pyridones were subjected to PDE3 inhibitory activity, 14 pyridones were found to be hits out of 26 pyridones synthesized and out of 14 hits, there are 5 pyridones found to be lead compounds having excellent PDE3 inhibitory activity. Further we have carried out computational analysis to understand protein/enzyme and 2-pyridone derivative interactions to identify amino acid residues involved in the vicinity of binding and compared with milrinone drug.

MATERIALS
Product Number
Brand
Product Description

Levetiracetam impurity C, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
2-Hydroxypyridine, 97%